Ginkgo Bioworks begins trading on the NYSE after SPAC merger with Soaring Eagle

Ginkgo Bioworks

Soaring Eagle shareholders approved the merger with Ginkgo Bioworks with 97% voting in favor, raising $1.63 billion in proceeds and marking the largest biotechnology go-public transaction. The combined company began trading on the NYSE under the ticker DNA on September 17, 2021.

• $1.63 billion in total proceeds: $775 million from PIPE funding and approximately $858 million from the Soaring Eagle trust.
• Ginkgo develops a platform to program cells like computer programming, with applications in food, fragrances, cosmetics, and medicines.
• Trading began on September 17, 2021; public warrants trade under DNA.WS.